Show simple item record

dc.contributorSoliman, A.R.EN
dc.contributorEl Meligi, A.A.EN
dc.contributorEl Semari, M.EN
dc.contributorEl Shemi, M.EN
dc.contributorMahmoud, H.EN
dc.date.accessioned2014-06-17T11:24:39Z
dc.date.available2014-06-17T11:24:39Z
dc.date.issued2003EN
dc.identifier.issn1020-3397EN
dc.identifier.otherhttp://applications.emro.who.int/emhj/0903/emhj_2003_9_3_399_406.pdfEN
dc.identifier.urihttp://www.who.int/iris/handle/10665/119290
dc.description399-406EN
dc.description.abstractSerum transforming growth factor-beta [‎TGF-beta1]‎ production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis [‎5 hypertensive and 7 normotensive]‎ and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis groupEN
dc.language.isoenEN
dc.subjectBlood Urea NitrogenEN
dc.subjectCase-Control StudiesEN
dc.subjectChronic DiseaseEN
dc.subjectCreatinineEN
dc.subjectGlomerulonephritisEN
dc.subjectHypertensionEN
dc.subjectImmunoassayEN
dc.subjectProteinuriaEN
dc.subject.meshAngiotensin-Converting Enzyme InhibitorsEN
dc.titlePossible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritisEN
dc.relation.ispartofjournalEMHJ - Eastern Mediterranean Health Journal, 9 (‎3)‎, 399-406, 2003


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record